文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

卡瑞利珠单抗联合或不联合新辅助化疗治疗可切除食管鳞状细胞癌:随机3期ESCORT-NEO/NCCES01试验

Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.
PubMed 文献 · Nat Med · 2024-07-02

这项多中心、随机、开放标签3期试验纳入391例可切除胸段局部晚期食管鳞状细胞癌患者,按1:1:1随机接受两周期新辅助卡瑞利珠单抗联合白蛋白结合型紫杉醇顺铂、卡瑞利珠单抗联合紫杉醇顺铂或单纯紫杉醇顺铂化疗后手术。意向治疗人群中,联合组病理完全缓解率分别为28.0%和15.4%,显著高于单纯化疗组的4.7%。

要点

  • 卡瑞利珠单抗联合白蛋白结合型紫杉醇顺铂组病理完全缓解率为28.0%,显著高于单纯化疗组的4.7%。
  • 卡瑞利珠单抗联合紫杉醇顺铂组病理完全缓解率为15.4%,显著高于单纯化疗组的4.7%。
  • 新辅助治疗期间≥3级治疗相关不良事件发生率三组分别为34.1%、29.2%和28.8%。

核心结论

  • 对于局部晚期食管鳞状细胞癌,新辅助卡瑞利珠单抗联合化疗较单纯化疗显示出更优的病理完全缓解率,安全性可耐受。
  • 研究达到病理完全缓解率的主要终点,但无事件生存期数据尚未成熟。

研究设计与样本

  • 多中心、随机、开放标签3期试验,纳入391例可切除胸段局部晚期食管鳞状细胞癌患者(T1b-3N1-3M0或T3N0M0)。
  • 按临床分期(I/II、III或IVA期)分层,按1:1:1随机接受两周期新辅助治疗:卡瑞利珠单抗联合白蛋白结合型紫杉醇顺铂组(n=132)、卡瑞利珠单抗联合紫杉醇顺铂组(n=130)或紫杉醇顺铂组(n=129),随后行手术切除。
  • 卡瑞利珠单抗联合白蛋白结合型紫杉醇顺铂组和卡瑞利珠单抗联合紫杉醇顺铂组术后还接受辅助卡瑞利珠单抗治疗。
  • 双主要终点为盲法独立审查委员会评估的病理完全缓解率和研究者评估的无事件生存期;本研究报告病理完全缓解率的最终分析。

主要发现

  • 意向治疗人群中,卡瑞利珠单抗联合白蛋白结合型紫杉醇顺铂组病理完全缓解率为28.0%,卡瑞利珠单抗联合紫杉醇顺铂组为15.4%,紫杉醇顺铂组为4.7%。
  • 卡瑞利珠单抗联合白蛋白结合型紫杉醇顺铂组对比紫杉醇顺铂组:差值23.5%(95%CI 15.1-32.0),P<0.0001。
  • 卡瑞利珠单抗联合紫杉醇顺铂组对比紫杉醇顺铂组:差值10.9%(95%CI 3.7-18.1),P=0.0034。
  • 新辅助治疗期间≥3级治疗相关不良事件发生率:卡瑞利珠单抗联合白蛋白结合型紫杉醇顺铂组34.1%,卡瑞利珠单抗联合紫杉醇顺铂组29.2%,紫杉醇顺铂组28.8%。
  • 术后并发症发生率分别为34.2%、38.8%和32.0%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 无事件生存期数据尚未成熟。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent single-arm studies involving neoadjuvant camrelizumab, a PD-1 inhibitor, plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC) have shown promising results. This multicenter, randomized, open-label phase 3 trial aimed to further assess the efficacy and safety of neoadjuvant camrelizumab plus chemotherapy followed by adjuvant camrelizumab, compared to neoadjuvant chemotherapy alone. A total of 391 patients with resectable thoracic LA-ESCC (T1b-3N1-3M0 or T3N0M0) were stratified by clinical stage (I/II, III or IVA) and randomized in a 1:1:1 ratio to undergo two cycles of neoadjuvant therapy. Treatments included camrelizumab, albumin-bound paclitaxel and cisplatin (Cam+nab-TP group; n = 132); camrelizumab, paclitaxel and cisplatin (Cam+TP group; n = 130); and paclitaxel with cisplatin (TP group; n = 129), followed by surgical resection. Both the Cam+nab-TP and Cam+TP groups also received adjuvant camrelizumab. The dual primary endpoints were the rate of pathological complete response (pCR), as evaluated by a blind independent review committee, and event-free survival (EFS), as assessed by investigators. This study reports the final analysis of pCR rates. In the intention-to-treat population, the Cam+nab-TP and Cam+TP groups exhibited significantly higher pCR rates of 28.0% and 15.4%, respectively, compared to 4.7% in the TP group (Cam+nab-TP versus TP: difference 23.5%, 95% confidence interval (CI) 15.1-32.0, P < 0.0001; Cam+TP versus TP: difference 10.9%, 95% CI 3.7-18.1, P = 0.0034). The study met its primary endpoint of pCR; however, EFS is not yet mature. The incidence of grade ≥3 treatment-related adverse events during neoadjuvant treatment was 34.1% for the Cam+nab-TP group, 29.2% for the Cam+TP group and 28.8% for the TP group; the postoperative complication rates were 34.2%, 38.8% and 32.0%, respectively. Neoadjuvant camrelizumab plus chemotherapy demonstrated superior pCR rates compared to chemotherapy alone for LA-ESCC, with a tolerable safety profile. Chinese Clinical Trial Registry identifier: ChiCTR2000040034 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Qin J, Xue L, Hao A, et al. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial. Nat Med. 2024. PMID: 38956195. doi:10.1038/s41591-024-03064-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。